MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Abbott Laboratories

Open

SectorGezondheidszorg

128.3 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

127.11

Max

130.1

Belangrijke statistieken

By Trading Economics

Inkomsten

7.6B

9.2B

Verkoop

339M

11B

K/W

Sectorgemiddelde

17.001

57.333

EPS

1.09

Dividendrendement

1.8

Winstmarge

84.099

Werknemers

114,000

EBITDA

82M

3B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+11.42% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.80%

2.63%

Volgende dividenddatum

15 mei 2025

Volgende Ex Dividend datum

14 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3B

225B

Vorige openingsprijs

129.2

Vorige sluitingsprijs

128.3

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Abbott Laboratories Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 apr 2025, 16:21 UTC

Winsten

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 apr 2025, 12:14 UTC

Winsten

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22 jan 2025, 19:03 UTC

Winsten

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 jan 2025, 18:20 UTC

Winsten

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 jan 2025, 12:45 UTC

Winsten

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16 apr 2025, 15:09 UTC

Marktinformatie

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 apr 2025, 14:17 UTC

Winsten

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 apr 2025, 11:34 UTC

Winsten

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 apr 2025, 11:33 UTC

Winsten

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 apr 2025, 11:32 UTC

Winsten

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 apr 2025, 11:32 UTC

Winsten

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 apr 2025, 11:31 UTC

Winsten

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Reaffirms Full-Yr Guidance

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Sales $10.36B >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Net $1.33B >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q EPS 76c >ABT

16 apr 2025, 11:30 UTC

Winsten

Abbott Labs 1Q Adj EPS $1.09 >ABT

16 apr 2025, 09:57 UTC

Populaire aandelen

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1 feb 2025, 18:14 UTC

Top Nieuws

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 jan 2025, 16:40 UTC

Top Nieuws
Winsten

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 jan 2025, 15:20 UTC

Winsten

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 jan 2025, 15:08 UTC

Winsten

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 jan 2025, 13:51 UTC

Winsten

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 jan 2025, 13:39 UTC

Top Nieuws
Winsten

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 jan 2025, 12:02 UTC

Winsten

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 jan 2025, 12:01 UTC

Winsten

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 jan 2025, 12:01 UTC

Winsten

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 jan 2025, 12:00 UTC

Winsten

Abbott Labs 4Q Net $9.23B >ABT

Peer Vergelijking

Prijswijziging

Abbott Laboratories Prognose

Koersdoel

By TipRanks

11.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 144.15 USD  11.42%

Hoogste 159 USD

Laagste 127 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Abbott Laboratories - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

18

Buy

3

Hold

0

Sell

Technische score

By Trading Central

128.52 / 129.7Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.